Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.74)
# 3,382
Out of 5,124 analysts
62
Total ratings
45.45%
Success rate
-2.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $21.70 | +52.07% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $107.04 | +46.67% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $34.57 | -13.22% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.32 | -24.24% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $29.81 | -26.20% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $11.31 | +32.63% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.61 | +260.11% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $37.42 | -25.17% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.60 | +3,900.00% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $33.87 | +443.25% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $3.01 | +597.67% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $40.40 | -65.35% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $7.57 | +2,013.61% | 2 | Dec 15, 2021 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $21.70
Upside: +52.07%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $107.04
Upside: +46.67%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $34.57
Upside: -13.22%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.32
Upside: -24.24%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $29.81
Upside: -26.20%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $11.31
Upside: +32.63%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.61
Upside: +260.11%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $37.42
Upside: -25.17%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.60
Upside: +3,900.00%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $33.87
Upside: +443.25%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.01
Upside: +597.67%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $40.40
Upside: -65.35%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $7.57
Upside: +2,013.61%